If our nanoparticles showed enhancement of the activity of the loaded drug (lower MIC than the free antibiotic) , but its not showing sustain release when using dialysis tube method, also it is stable in phosphate buffer (the media for release).
is it mandatory that all nanoparticles should shows sustain release, or we can just accept the other advantages of these nanoparticles over the free drug!
I think the answer depends on how you intend to use the nanoparticles. Sustained release may be a requirement for some applications, but unnecessary or undesirable for others.
Yes, you need to show the release of the drug. Any delivery system main function is release of the drug to site, that contributes to the rate and extent of active availability to the biological system. A delivery agent determines the pharmacodynamics and Pharmacokinetics of any drug.
Otherwise we won't go for designing advance/smart/nanosize delivery system.
Even, the activity which you mentioned, it could be due to nanoparticles itself not of antibiotic (in term of MIC what u got more in drug loaded nanoparticle). Hope u had checked only nanoparticle activity also.
Nano-particles are smart candidate for next-generation level research. But when we come up with nanoparticles for biological entities, we need to assure every pros & cons.
cheers!!!
I think the answer depends on how you intend to use the nanoparticles. Sustained release may be a requirement for some applications, but unnecessary or undesirable for others.
Thank you Saurabh Mandal & Adam B Shapiro , for your answers, yes i did MIC for my blank formula, and it have some activity but very week.
I did release study for my formula and i found it release the drug, but my problem is that the rate of release is quick, when you compare it with the release of the bare drug there is no big difference,
here is my question is it necessary to show sustain release ! also the nanoparicles shows around 50% entrapment of the drug, i'm using dialysis tube method.
and for Adam question , we intended to deliver it IV for treat bacterial infection.
I don't usually associate sustained release with IV drug delivery. I did a little work on nanoparticulate formulation of an antibacterial compound. The goals were (1) to improve the pharmacokinetics of a drug with high clearance by reducing the clearance, (2) to achieve an increased concentration of the drug at the tissue site of infection due to the enhanced permeability and retention effect, and (3) to increase efficacy of the drug. All 3 goals were achieved. I did not investigate whether there was sustained release. In vivo efficacy experiments for acute infections typically only last 1 day, which is probably not long enough to study sustained release.
Thank you Dr. Adam
If you published this work please can you send me the article
and thank you for sharing this information , really it will help me.
Here is a link to the article:
Article Improvement of the Pharmacokinetics and In Vivo Antibacteria...
- Badges
- Science method